Table 2. Characteristics of included studies (HBcAb).
| Study | Publication year | Country | Type of study | SLE patients(n) | Controls(n) | Control description | Matching and adjustments |
HBcAb detection | NOS score | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Wang F, et al., | 2016 | China | Prospective | 346 | 12779 | Healthy subjects | Age and sex | NA | 6 | 14 |
| Watanabe R, et al. | 2014 | Japan | Retrospective | 248 | 703 | RA | NA | NA | 6 | 16 |
| Ram M, et al. | 2008 | Israel | Prospective | 117 | 140 | Individuals without inflammatory, autoimmune disease or history of chronic infection | Age and sex | Elisa | 7 | 25 |
| Berkun Y, et al. | 2009 | Israel | Prospective | 120 | 140 | Without known inflammatory or autoimmune disease | Age and sex | BioPlex 2200 Multiplexed Immunoassay method |
7 | 26 |
| Lu CL, et al. | 1997 | Taiwan, China | Prospective | 173 | 222 | Healthy subjects | Age and sex | Radioimmunoassay kits | 8 | 19 |
| Wu CX, et al. | 2015 | China | Retrospective | 176 | 194 | RA | Age and sex | NA | 5 | 22 |
| Qiu N, et al. | 2001 | China | Prospective | 102 | 64 | Non-SLE inpatients | NA | Elisa | 5 | 23 |